RT Journal Article
SR Electronic
T1 Plasma sgp130 is an independent predictor of non-alcoholic fatty liver disease severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.10.22268968
DO 10.1101/2022.01.10.22268968
A1 Aysim Gunes
A1 Laurent Bilodeau
A1 Catherine Huet
A1 Assia Belblidia
A1 Cindy Baldwin
A1 Jeanne-Marie Giard
A1 Laurent Biertho
A1 Annie Lafortune
A1 Christian Yves Couture
A1 Bich N Nguyen
A1 Eithan Galun
A1 Chantal Bémeur
A1 Marc Bilodeau
A1 Mathieu Laplante
A1 An Tang
A1 May Faraj
A1 Jennifer L. Estall
YR 2022
UL http://medrxiv.org/content/early/2022/04/25/2022.01.10.22268968.abstract
AB Background Interleukin-6 (IL-6) plays important and dynamic roles in inflammation associated with fatty liver disease over all stages, from simple steatosis to steatohepatitis, cirrhosis and cancer. IL-6 signals locally, but also circulates with multiple co-factors that control paracrine and endocrine signaling. As inflammation is a main driver of liver fibrosis, we investigated relationships between circulating components of the interleukin-6 signaling pathway (IL-6, sIL-6R and sgp130) and liver pathology in subjects with metabolically associated fatty liver disease (MAFLD) or steatohepatitis (MASH).Methods Predictive performances of plasma IL-6, sIL-6R and sgp130 were investigated in two independent cohorts: 1) patients with biopsy-confirmed MASH (n=49), where magnetic resonance spectroscopy (MRS), imaging (MRI) and elastography (MRE) assessed liver fat, volume and stiffness; and 2) patients with morbid obesity (n=245) undergoing bariatric surgery where histological staging of steatosis, activity, and fibrosis determined MASH severity. Correlations were evaluated between IL-6, sIL-6R and sgp130 and anthropomorphic characteristics, plasma markers of metabolic disease or liver pathology.Results In patients with MASH, plasma IL-6 and sgp130 strongly correlated with liver stiffness, which for sgp130 was independent of age, sex, BMI, diabetes, hyperlipidemia, hypertension or history of HCC. Plasma sgp130 was the strongest predictor of liver stiffness compared to common predictors and risk scores. Plasma sIL-6R correlated with liver volume independent of age, sex, and BMI. In patients with morbid obesity, circulating sgp130 correlated with advanced liver fibrosis.Conclusion Levels of circulating sgp130 can predict progressing MASH and may be used alone or in combination with other predictors as a non-invasive measure of liver disease severity.Competing Interest StatementLaurent Biertho receives funding from Johnson & Johnson Medical Companies, Medtronic, Bodynov and GI Windows for studies on bariatric surgery. An Tang and Jennifer Estall received a speaking honorarium from Eli Lilly.Funding StatementThis work was supported by unrestricted operating grants from the Merck, Sharpe and Dohme Corporation/University of Montreal and the International Development Research Centre (108591-001). JLE and AT are supported by Chercheurs-boursiers: Senior awards from the Fonds de recherche du Quebec Sante. The ULaval Biobank is supported by the IUCPQ Foundation and Research Center.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committees of the: Centre hospitalier de Universite de Montreal; Institut de recherches clinique de Montreal; and Institut universitaire de cardiologie et de pneumologie de Quebec, Universite Laval gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors